You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Low Disability Accumulation After 4-Year Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis: Data From the Phase IIIb ENSEMBLE Study
As MS is a progressive disease from the onset, initial and sustained treatment with high-efficacy therapies is important to maintain patient function. Here, we report the 4-year disability progression and efficacy data from patients with relapsing-remitting MS who received first-line OCR therapy.
Request medical material
Would you like to receive this poster via email to view later?